此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy (OSEM)

2026年11月10日 更新者:UNCANCER LLC

A Randomized Pilot Study of the OSEM Oral Side-Effect Management Program in Adults Receiving Head and Neck Radiation Therapy at Premier Cancer Center

People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, and changes in taste. These problems can become severe enough to interrupt radiation treatment or lead to an emergency room visit or a hospital stay.

This study is testing whether an oral care program called OSEM (Oral Side-Effect Management) reduces how severe those mouth problems become.

Fifty adults starting radiation to a head and neck site at Premier Cancer Center will take part. Each person will be assigned by chance, like a coin toss, to one of two groups:

One group receives the Peace of Mouth Kit - everyday mouth care products including dry mouth candies, ginger candies for nausea, a mouth rinse, a sensitivity toothpaste, a soft toothbrush and a lip balm - together with a short check-in each week with a member of the Premier team right after their radiation treatment.

The other group receives their usual care at Premier, unchanged.

Everyone in the study fills out the same short questionnaire about their mouth each week during radiation, and once more about four weeks after their last treatment. Everyone continues to see their radiation doctor every week, exactly as they would if they were not in the study.

Taking part lasts about 11 weeks in all.

The items in the kit are everyday consumer mouth care products. They are not medicines of any kind, and the U.S. Food and Drug Administration has not approved them to treat or prevent any disease.

研究概览

详细说明

BACKGROUND

Oral toxicity is among the most burdensome consequences of head and neck radiation therapy. Mucositis, xerostomia, dysgeusia, mucosal pain and impaired oral intake develop during treatment, peak in the later treatment weeks, and can persist for weeks afterwards. Their consequences are not confined to discomfort: reduced oral intake leads to weight loss and dehydration, pain and mucosal injury lead to unplanned clinic and emergency visits, and severe toxicity can interrupt radiation delivery, which is itself associated with poorer disease control.

The OSEM (Oral Side-Effect Management) program combines a baseline structural risk assessment, a weekly patient-reported outcome instrument, a supportive-care product kit, and structured weekly review by a clinical coordinator with a defined escalation pathway to the treating radiation oncologist. No controlled evidence establishes that the program reduces oral symptom severity. That is the question this study asks.

THE INTERVENTION IS A BUNDLE

The test-arm intervention is delivered as a bundle and this study cannot attribute an observed effect to any single component. That limitation is accepted deliberately: the program is delivered as a bundle in practice, and a study of this size cannot support a factorial design. Component attribution is a question for a subsequent trial.

BLINDING

Participants and site staff cannot be blinded, since a kit is either received or not. Three mitigations apply. The primary endpoint is patient-reported and is collected identically in both arms, on the same schedule and in the same mode. Secondary clinical endpoints are adjudicated by a reviewer blinded to allocation, working from records with allocation redacted. The statistician conducting the primary analysis is blinded to arm identity until the analysis is locked.

BASELINE RISK SCORING

An OSEM Stage 1 baseline risk score is computed for every participant in both arms before the first delivered radiation fraction. It is recorded for research only. It is not returned to the participant or to the treating team in either arm, and it does not inform clinical management.

WHAT IS COMMON TO BOTH ARMS AND WHAT IS NOT

The weekly questionnaire is completed by the participant at Premier, ordinarily on the day of the scheduled radiation oncologist visit, and is identical in both arms. Weekly review by the clinical coordinator, the severity band that review acts on, and the escalation pathway are features of the intervention arm only.

Standard of care is unchanged in both arms, including the weekly radiation oncologist assessment and the after-hours on-call service. Nothing is withheld from control participants, and the kit components and equivalent products remain commercially available to anyone.

STATISTICAL APPROACH

This is a pilot study. The primary analysis compares the standardized area under the weekly oral symptom score curve between arms using analysis of covariance, adjusted for the stratification factor and for the baseline oral symptom score, with the treatment effect reported as an adjusted mean difference with a confidence interval. Where the distribution is materially non-normal, a prespecified rank-based alternative is used and the parametric result reported alongside.

No hypothesis test is prespecified for the binary clinical event endpoints, because the study is not powered for them. They are reported as proportions with exact confidence intervals and risk differences. A principal purpose of the study is to estimate the parameters needed to design an adequately powered confirmatory trial.

LIMITATIONS

Premier Cancer Center is a freestanding radiation oncology practice. Capture of acute care received outside Premier is incomplete, and completeness is reported as a limitation by arm rather than assumed.

In a head and neck cohort, concurrent chemoradiation triggers an automatic high-risk condition in the Stage 1 model, so baseline risk variation is limited by design. No claim about Stage 1 discriminative performance can be made from this study.

研究类型

介入性

注册 (估计的)

50

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Florida
      • Clearwater、Florida、美国、33765-1703
        • 招聘中
        • Premier Cancer Center
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Adults aged 18 years or older Histologically confirmed malignancy of a head and neck site Planned definitive or post-operative external beam radiation therapy to a head and neck site, delivered at Premier Cancer Center Planned course of at least 20 fractions over approximately 4 to 7 weeks With or without concurrent systemic therapy Able to provide written informed consent Able to complete an electronic questionnaire in English, with or without assistance

Exclusion Criteria:

Palliative short-course radiation, or a planned course of fewer than 20 fractions Re-irradiation of a previously irradiated head and neck field Radiation delivered at an institution other than Premier Known allergy or sensitivity to any component of the Peace of Mouth Kit Any condition that, in the judgment of the treating radiation oncologist or the Premier Physician of Record, makes participation unsafe or impracticable Inability to complete study assessments

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:OSEM Program

Participants receive the Peace of Mouth Kit at enrollment, at approximately week 5, and at the final treatment visit in week 7 - three kits in total - together with a structured review by the Premier clinical coordinator each week, immediately after radiation treatment.

The weekly review consists of a fixed set of safety-flag questions, review of the participant's weekly symptom band and red-flag status, and assessment of kit use. Where the band or a red-flag criterion indicates it, the coordinator escalates directly to the on-call Premier radiation oncologist, who determines clinical management. The study does not direct clinical management.

Premier standard of care continues unchanged, including the weekly radiation oncologist assessment and the after-hours on-call service.

A kit of six commercially available consumer oral care products, supplied at enrollment, at approximately week 5, and at the final treatment visit in week 7 - three kits in total, each a one-month supply.

Each kit contains: dry mouth candies, 6 packs, xylitol-based, 3 lemon and 3 sour cherry; nausea candies, 1 pack, ginger, xylitol-based; soothing mouth rinse, 30 single-dose stick packs of sodium chloride and sodium bicarbonate, one per day; sensitivity toothpaste with 10% nano-hydroxyapatite and xylitol, 3 oz; a soft bamboo-handled toothbrush; and a lip balm. A reusable bottle for preparing the daily rinse comes with the first kit only.

Use is at the participant's discretion, following written instructions in each kit. Participants may stop any component at any time and are told to do so if it causes discomfort.

No component is a prescription or over-the-counter drug, and none is FDA-approved to treat or prevent any disease.

其他名称:
  • OC ORAL CARE KIT
  • PEACE OF MOUTH KIT
无干预:STANDARD OF CARE

Participants receive Premier standard of care without modification, including the weekly radiation oncologist assessment, the after-hours on-call service, and any supportive-care measure the treating team judges appropriate.

Participants complete the same baseline and weekly symptom questionnaire as the intervention arm, for research purposes only. The resulting symptom band is computed and retained for analysis but is not reviewed for escalation, is not returned to anyone, and does not generate any contact. There is no kit, no clinical coordinator review and no safety-flag questions.

Kit components and equivalent products remain commercially available, and nothing is withheld from participants in this arm.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Oral symptom burden: area under the weekly oral symptom score curve
大体时间:From the first delivered radiation fraction (Time 0) through the end-of-treatment assessment, up to 7 weeks and the a 4 week end of trial follow up.

The weekly oral symptom score is the sum of eight patient-reported oral symptom domains - mouth pain, mouth sores, dry mouth, dry or chapped lips, taste changes, trouble eating or drinking, nausea when eating or drinking, and dizziness or dark urine - each graded on a four-level scored severity collapse. The score ranges from 0 to 42, where a higher score indicates greater symptom burden. Area under the curve is computed by the trapezoidal rule across available weekly assessments and standardized for the number of assessments contributed, so that participants with different course lengths are comparable. A lower area under the curve indicates lower symptom burden across the radiation course.

From the first delivered radiation fraction (Time 0) through the end-of-treatment assessment, up to 7 weeks and the a 4 week end of trial follow up.

次要结果测量

结果测量
措施说明
大体时间
Peak oral symptom severity
大体时间:From Time 0 through the end-of-treatment assessment, up to 7 weeks and then a final follow up 4 weeks later

The highest weekly oral symptom score recorded during the radiation course, on the same 0 to 42 scale as the primary outcome measure, where a higher score indicates greater symptom burden.

From Time 0 through the end-of-treatment assessment, up to 7 weeks and then a final follow up 4 weeks later
Time to first moderate or worse oral symptom
大体时间:From Time 0 through the end-of-treatment assessment, up to 7 weeks and then a final follow up 4 weeks later

Time from the first delivered radiation fraction to the first weekly assessment at which any of the eight scored oral symptom domains is recorded at moderate severity or worse.

From Time 0 through the end-of-treatment assessment, up to 7 weeks and then a final follow up 4 weeks later
Proportion of participants reaching severe or very severe oral symptom severity
大体时间:From Time 0 through the end-of-treatment assessment, up to 7 weeks and then a final follow up 4 weeks later

The proportion of participants in whom any of the eight scored oral symptom domains is recorded at severe or very severe at any weekly assessment.

From Time 0 through the end-of-treatment assessment, up to 7 weeks and then a final follow up 4 weeks later
Unplanned acute-care use attributable to oral toxicity
大体时间:From Time 0 through the follow-up assessment 4 weeks after the final radiation fraction, up to 11 weeks

Number of participants with at least one emergency department or urgent care evaluation, or hospitalization, attributable to oral toxicity, impaired oral intake or associated dehydration. Events are ascertained from the Premier medical record and adjudicated by a reviewer blinded to arm allocation. Capture of care received outside Premier is incomplete, and completeness is reported by arm.

From Time 0 through the follow-up assessment 4 weeks after the final radiation fraction, up to 11 weeks
Unplanned radiation treatment interruption attributable to oral toxicity
大体时间:From Time 0 through the final radiation fraction, up to 7 weeks

Number of participants with at least one unplanned interruption of radiation delivery attributable to oral toxicity. Occurrence is confirmed from the radiation delivery record and cause from the treating clinician's documentation, adjudicated by a reviewer blinded to arm allocation.

From Time 0 through the final radiation fraction, up to 7 weeks
Enteral or parenteral nutrition escalation attributable to oral toxicity
大体时间:From Time 0 through the follow-up assessment 4 weeks after the final radiation fraction, up to 11 weeks

Number of participants with new or escalated enteral or parenteral nutrition support attributable to oral toxicity, adjudicated by a reviewer blinded to arm allocation.

From Time 0 through the follow-up assessment 4 weeks after the final radiation fraction, up to 11 weeks
Change in body weight
大体时间:Baseline, end of treatment (up to 7 weeks), and follow-up 4 weeks after the final radiation fraction (up to 11 weeks)

Change in measured body weight from the enrollment baseline to the end-of-treatment assessment, and from the enrollment baseline to the follow-up assessment. Reported in kilograms and as a percentage of baseline weight.

Baseline, end of treatment (up to 7 weeks), and follow-up 4 weeks after the final radiation fraction (up to 11 weeks)
Oral symptom burden at the follow-up assessment
大体时间:Follow-up assessment 4 weeks after the final radiation fraction, up to 11 weeks

The weekly oral symptom score recorded at the follow-up assessment, on the same 0 to 42 scale as the primary outcome measure, where a higher score indicates greater symptom burden.

Follow-up assessment 4 weeks after the final radiation fraction, up to 11 weeks

其他结果措施

结果测量
措施说明
大体时间
ePRO completion rate
大体时间:From Time 0 through the follow-up assessment, up to 11 weeks

The proportion of scheduled ePRO assessments that were submitted, out of the number expected.

An assessment is expected at enrollment, in each week a participant is on treatment, and once at the follow-up visit. No item may be skipped, so a submitted assessment is complete by construction: this measure counts whole assessments submitted, not items answered. A missed assessment is recorded with the reason where known.

Reported as a percentage, overall and by week, for each arm. A higher percentage indicates more complete data capture.

This measure applies to both arms. The instrument, the schedule and the mode of administration are identical in each.

From Time 0 through the follow-up assessment, up to 11 weeks
Clinical coordinator weekly review completion rate
大体时间:From Time 0 through the final radiation fraction, up to 7 weeks

The proportion of scheduled weekly clinical coordinator reviews that were completed and documented, out of the number expected.

A review is expected in each week a participant is on treatment. A review counts as completed when the six safety-flag questions have been asked, the band and red-flag status reviewed, kit use assessed, and the review recorded. Reviews not completed are recorded as missed, together with the reason.

Reported overall and by week, as a percentage. A higher percentage indicates that the weekly review ran as specified.

This measure applies to the OSEM Program arm only. The Standard of Care arm receives no clinical coordinator review.

From Time 0 through the final radiation fraction, up to 7 weeks
Time from Stage 2 band review to escalation contact
大体时间:From Time 0 through the final radiation fraction, up to 7 weeks

Time elapsed from the clinical coordinator's completion of the weekly Stage 2 band and red-flag review to the first documented contact with the on-call Premier radiation oncologist, measured in hours.

Both time points are recorded in the study escalation log at the time they occur. The measure is evaluated only for reviews at which the band or a confirmed red-flag criterion indicated escalation.

This measure applies to the OSEM Program arm only. No band review and no escalation pathway operate in the Standard of Care arm, so no value exists for that arm and none is reported.

A shorter time indicates faster escalation. The measure is reported descriptively, as a feasibility measure of whether the escalation pathway operates as specified. It is not a comparison between arms.

From Time 0 through the final radiation fraction, up to 7 weeks
Participant-reported kit use
大体时间:From Time 0 through the final radiation fraction, up to 7 weeks

Participant self-report of how often each kit component was used in the preceding 7 days, collected on the weekly ePRO.

Each of the six components - soothing mouth rinse, sensitivity toothpaste, dry mouth candies, nausea candies, soft toothbrush and lip balm - is answered on a four-level scale: Not at all, A few times, Most days, Every day. The item is not scored and does not contribute to the oral symptom score or the severity band.

This measure applies to the OSEM Program arm only, since the Standard of Care arm receives no kit.

Reported descriptively as the distribution of responses by component and by week. A higher proportion answering Most days or Every day indicates greater adherence.

From Time 0 through the final radiation fraction, up to 7 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:ABIDA TAHER、UNCANCER LLC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年12月1日

研究注册日期

首次提交

2026年10月13日

首先提交符合 QC 标准的

2026年10月13日

首次发布 (实际的)

2026年10月21日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified participant-level data supporting the published results will be made available, together with the Statistical Analysis Plan and the analysis code. The frozen OSEM model specification, build identifier and cryptographic hashes are also made available, so that any published score can be independently reconstructed.

IPD 共享时间框架

Beginning 12 months after publication of the primary results and ending 5 years after publication.

IPD 共享访问标准

Who: qualified researchers with a methodologically sound proposal and a stated analytic purpose.

What: the de-identified participant-level dataset supporting the published results, the Statistical Analysis Plan, the analysis code, and the frozen OSEM model specification with its build identifier and cryptographic hashes, so that any published score can be independently reconstructed.

How: requests are submitted in writing to the study office and are reviewed by the Principal Investigator and the study biostatistician. A data use agreement must be executed before any transfer, under which the requester agrees not to attempt re-identification of participants and not to transfer the data to third parties.

Release is subject to the de-identification standard applied to the dataset and to any restriction in the executed site and sponsor agreements.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅